Page last updated: 2024-10-31

nafamostat and Heart Disease, Ischemic

nafamostat has been researched along with Heart Disease, Ischemic in 2 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Research Excerpts

ExcerptRelevanceReference
" The dose-response characteristics of these three protease inhibitors were bell shaped, and the optimal concentrations of nafamostat mesilate, gabexate mesilate, and NCO-700 were 5 microM, 100 microM, and 20 microM, respectively."1.30Effects of protease inhibitors on postischemic recovery of the heart. ( Kinoshita, H; Shibata, T; Suehiro, S; Yamamoto, F, 1997)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schwertz, H1
Längin, T1
Platsch, H1
Richert, J1
Bomm, S1
Schmidt, M1
Hillen, H1
Blaschke, G1
Meyer, J1
Darius, H1
Buerke, M1
Shibata, T1
Yamamoto, F1
Suehiro, S1
Kinoshita, H1

Other Studies

2 other studies available for nafamostat and Heart Disease, Ischemic

ArticleYear
Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits.
    Proteomics, 2002, Volume: 2, Issue:8

    Topics: alpha-Crystallin B Chain; Animals; Benzamidines; Creatine Kinase; Electrophoresis, Gel, Two-Dimensio

2002
Effects of protease inhibitors on postischemic recovery of the heart.
    Cardiovascular drugs and therapy, 1997, Volume: 11, Issue:4

    Topics: Animals; Benzamidines; Creatine Kinase; Gabexate; Glycoproteins; Guanidines; Heart; In Vitro Techniq

1997